We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients

cell-1
cell-2
cell-3
cell-4
cell-5
cell-6

Spotlight

Curis Corporate Presentation

View our Current Corporate Presentation here.

Curis Corporate Presentation

Curis – Emavusertib (IRAK4i)

At Curis, we are developing differentiated therapeutics with the goal of improving the lives of cancer patients. Our new animation shows how Emavusertib (CA-4948) is being developed to target hematologic malignancies and other cancers

you must enable cookies to view this content

Press Releases

Pipeline

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
Emavusertib*
IRAK4
 IRAK4-driven Leukemia
(AML/MDS)

TakeAim Leukemia

Emavusertib*
IRAK4
 IRAK4-driven Lymphoma
(NHL, CLL, WM)

TakeAim Lymphoma

Fimepinostat
HDAC/PI3K
 MYC-altered Cancers

Immune Checkpoint Inhibitors
CA-327*
TIM3/PDL1
 PDL1/TIM3-expressing Cancers

CA-170**
VISTA/PDL1
 PDL1/VISTA-expressing Cancers

Approved Drug
Erivedge***
Hedgehog
 Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
Emavusertib*
IRAK4
 IRAK4-driven Leukemia
(AML/MDS)		Clinical Activity
Emavusertib*
IRAK4
 IRAK4-driven Lymphoma
(NHL, CLL, WM)		Clinical Activity
Fimepinostat
HDAC/PI3K
 MYC-altered CancersClinical Activity
Immune Checkpoint Inhibitors
CA-327*
TIM3/PDL1
 PDL1/TIM3-expressing CancersProof of Principle
CA-170**
VISTA/PDL1
 PDL1/VISTA-expressing CancersClinical Activity
Approved Drug
Erivedge***
Hedgehog
 Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** IP licensed to Aurigene
*** IP licensed to Genentech

Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development.